Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and the overall survival of resistant patients in the chronic phase who changed a second-generation TKI in the second line with another TKI with similar action are usually poor, while the off-target toxicities and the potential development of mutations increase. The recent approval of asciminib, a STAMP inhibitor, in the third line, has the potential to soon change the therapeutic algorithm for this subset of patients. Here, we report the results of a GIMEMA survey assessing the number of patients currently treated in the third line in Italy, the current approach in later lines by Italian physicians, and the future role of this drug according to the reason to switch to asciminib (resistance and/or intolerance), as well as the perceptions about the future position of this agent.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455524PMC
http://dx.doi.org/10.3390/jcm12165267DOI Listing

Publication Analysis

Top Keywords

lines chronic
8
chronic myeloid
8
myeloid leukemia
8
gimema survey
8
italian physicians'
4
physicians' perceptions
4
perceptions role
4
role asciminib
4
asciminib lines
4
leukemia clinical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!